Biodesix, Inc. (BDSX)
NASDAQ: BDSX · Real-Time Price · USD
0.882
-0.039 (-4.22%)
Feb 21, 2025, 4:00 PM EST - Market closed
Biodesix Revenue
Biodesix had revenue of $18.15M in the quarter ending September 30, 2024, with 34.54% growth. This brings the company's revenue in the last twelve months to $65.56M, up 48.92% year-over-year. In the year 2023, Biodesix had annual revenue of $49.09M with 28.46% growth.
Revenue (ttm)
$65.56M
Revenue Growth
+48.92%
P/S Ratio
1.56
Revenue / Employee
$302,129
Employees
217
Market Cap
128.30M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
BDSX News
- 4 days ago - Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 - GlobeNewsWire
- 6 weeks ago - Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited) - GlobeNewsWire
- 6 weeks ago - Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study - GlobeNewsWire
- 4 months ago - Biodesix, Inc. (BDSX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Biodesix Announces Third Quarter 2024 Results and Highlights - GlobeNewsWire
- 4 months ago - Biodesix to Participate in Three Investor Conferences in November - GlobeNewsWire
- 4 months ago - Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024 - Business Wire
- 4 months ago - Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study - Business Wire